New POINT research study to determine effectiveness of aspirin and clopidogrel given together in the treatment of mild stroke and TIA's to be done at UTSW Medical Center, Parkland and Texas Health Presbyterian Dallas.

POINT(Platelet Oriented Inhibition in New TIA) patient recruitment initiated in May 2010. POINT is a randomized, double-blind, multicenter clinical trial. The purpose of this study is to determine the safety and effectiveness of the combination of low-dose aspirin and a medication called clopidogrel (also known by the brand name Plavix®) in reducing the risk of stroke, heart attacks and other complications in patients who have just had a TIA or minor ischemic stroke. Done for 90 days and initiated within 12 hours of time last known free of new ischemic symptoms of TIA or minor ischemic stroke in subjects receiving aspirin 50-325mg/day.